Multi Vessel Coronary Artery Disease

5

Review clinical trials related to Multi Vessel Coronary Artery Disease. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Timing of FFR-guided PCI for Non-IRA in NSTEMI and MVD (OPTION-NSTEMI)

Many patients with non-ST-segment elevation myocardial infarction (NSTEMI) have multivessel coronary artery disease (MVD), which is associated with poor clinical outcomes. However, there have been few studies regarding revascularization strategy in patients with NSTEMI and MVD. Therefore, we planned to perform prospective, open-label, randomized trial to evaluate the efficacy and safety of immediate complete revascularization (percutaneous coronary intervention \[PCI\] for both infarct-related artery \[IRA\] and non-IRA during index PCI) compared to staged PCI strategy of non-IRA (PCI for IRA followed by non-IRA PCI after several days). PCI procedure at non-IRA with diameter stenosis between 50 and 69% should be conducted with the aid of fractional flow reserve (FFR), and non-IRA with diameter stenosis ≥ 70% will be revascularized without FFR.

Participants needed: 1,014
Trial details
Age: 19+Biological sex: AllType: InterventionalSponsor: Chonnam National University HospitalUpdated: Apr 27, 2026Locations: 1
Eligibility criteria

Age ≥ 19 years old [+11]

Cardiogenic shock at initial presentation or after treatment of IRA [+10]

Status: Not yet recruiting

Clinical Impact of DCB-based Versus DES-based Intervention in Patients With MVCAD

This study aimes to compare the clinical outcomes of drug-coated balloon-based percutaneous coronary intervention (DCB-based PCI) and drug-eluting stent-based percutaneous coronary intervention (DES-based PCI) in patients with multivessel coronary artery lesions measuring 2.25 mm to 4.0 mm in diameter through a prospective, multicenter, active-controlled, randomized, investigator-initiated clinical trial.

Participants needed: 892
Trial details
Age: 20+Biological sex: AllType: InterventionalSponsor: Genoss Co., Ltd.Updated: Apr 20, 2026
Eligibility criteria

Male or female adults aged 20 years or older with stable angina, silent myocardi... [+5]

Cardiogenic shock or patients requiring mechanical or pharmacological circulator... [+6]

Status: Recruiting

Revascularization Strategy of Multivessel Disease for Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Veno-arterial Extracorporeal Membrane Oxygenator

This study is a prospective, open-label, two-arm, randomized multicenter trial to identify whether immediate multi-vessel PCI would be better in clinical outcomes compared with culprit lesion-only PCI for AMI and multi-vessel disease with an advanced form of CS patients who require veno-arterial extracorporeal membrane oxygenator (VA-ECMO).

Participants needed: 560
Trial details
Phase: Phase 4Age: 19+Biological sex: AllType: InterventionalSponsor: Samsung Medical CenterUpdated: Nov 6, 2024Locations: 1
Eligibility criteria

Subject must be at least 19 years of age [+3]

Other causes of shock (hypovolemia, sepsis, obstructive shock). [+8]

Status: Recruiting

Practice Change With Drug-coated Balloon in Patients With multiVessel Coronary Artery Disease

This study is a prospective, multicenter, open-label, observational study to investigate the impact of using drug-coated balloons (DCBs) in the treatment of coronary artery lesions in patients with multivessel coronary artery disease (MVD), as opposed to the default strategy of using only drug-eluting stents (DES). The investigators aim to assess changes in clinical practice towards a hybrid treatment strategy (DES and DCB) and its effects on clinical outcomes.

Participants needed: 500
Trial details
Age: 19-100Biological sex: AllType: ObservationalSponsor: Bon-Kwon KooUpdated: Oct 27, 2023Locations: 1Duration: 1 Year
Eligibility criteria

Age 19 or older [+4]

Incapable of voluntarily providing informed consent [+6]

Status: Recruiting

PRospective Evaluation of Complete Revascularization in Patients With multiveSsel Disease Excluding chroNic Total Occlusions

This prospective, multicenter, non-randomized, single arm, objective performance goal (OPG) study is designed to evaluate clinical outcomes after complete revascularization by PCI and imaging guidance (OCT) in patients with multivessel coronary artery disease including left anterior descending (LAD) presenting with stable angina, or documented silent ischemia, or non-ST segment elevation acute coronary syndrome (NSTE-ACS).

Participants needed: 609
Trial details
Age: 18-85Biological sex: AllType: InterventionalSponsor: Erasmus Medical CenterUpdated: Feb 9, 2022Locations: 1
Eligibility criteria

Age ≥ 18 years, ≤85 years [+4]

Age <18 years and > 85 years. [+13]